Cytokinetics Amends ALS Therapy Trial After Mistake

Cytokinetics Inc., the developer of an experimental drug for amyotrophic lateral sclerosis, said it will increase the number of patients in a trial of the therapy after some were given a placebo by mistake.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.